DE69729473T2 - Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems - Google Patents

Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems Download PDF

Info

Publication number
DE69729473T2
DE69729473T2 DE69729473T DE69729473T DE69729473T2 DE 69729473 T2 DE69729473 T2 DE 69729473T2 DE 69729473 T DE69729473 T DE 69729473T DE 69729473 T DE69729473 T DE 69729473T DE 69729473 T2 DE69729473 T2 DE 69729473T2
Authority
DE
Germany
Prior art keywords
patient
apoe
patients
apoe4
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69729473T
Other languages
German (de)
English (en)
Other versions
DE69729473D1 (de
Inventor
Judes Poirier
Heiko Wiebusch
Keith Schappert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Nova Molecular Inc
Original Assignee
McGill University
Nova Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University, Nova Molecular Inc filed Critical McGill University
Publication of DE69729473D1 publication Critical patent/DE69729473D1/de
Application granted granted Critical
Publication of DE69729473T2 publication Critical patent/DE69729473T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69729473T 1996-12-16 1997-12-16 Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems Expired - Lifetime DE69729473T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/766,975 US6022683A (en) 1996-12-16 1996-12-16 Methods for assessing the prognosis of a patient with a neurodegenerative disease
US766975 1996-12-16
PCT/IB1997/001648 WO1998027227A2 (en) 1996-12-16 1997-12-16 Pharmacogenetic methods for use in the treatment of nervous system diseases

Publications (2)

Publication Number Publication Date
DE69729473D1 DE69729473D1 (de) 2004-07-15
DE69729473T2 true DE69729473T2 (de) 2005-06-09

Family

ID=25078098

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69729473T Expired - Lifetime DE69729473T2 (de) 1996-12-16 1997-12-16 Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
DE69729654T Expired - Lifetime DE69729654T2 (de) 1996-12-16 1997-12-16 Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69729654T Expired - Lifetime DE69729654T2 (de) 1996-12-16 1997-12-16 Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit

Country Status (8)

Country Link
US (2) US6022683A (https=)
EP (2) EP0946753B1 (https=)
JP (4) JP2001524809A (https=)
AT (1) ATE269978T1 (https=)
AU (2) AU5571798A (https=)
CA (2) CA2275404C (https=)
DE (2) DE69729473T2 (https=)
WO (2) WO1998027226A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US6441149B1 (en) 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6218117B1 (en) 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
US6489095B2 (en) 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6291175B1 (en) 1998-06-16 2001-09-18 Variagenics, Inc. Methods for treating a neurological disease by determining BCHE genotype
CA2354544A1 (en) 1998-10-01 2000-04-13 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
AU773329B2 (en) * 1999-05-14 2004-05-20 Proteomedica Ab Materials and methods relating to disease diagnosis
AU5638600A (en) * 1999-06-25 2001-01-31 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001069261A2 (en) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia
US20020006959A1 (en) * 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
US8124589B2 (en) * 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
US20030104453A1 (en) * 2001-11-06 2003-06-05 David Pickar System for pharmacogenetics of adverse drug events
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030224446A1 (en) * 2001-12-20 2003-12-04 Harry G. Jean Method of predicting cytokine response to tissue injury
US20040267458A1 (en) * 2001-12-21 2004-12-30 Judson Richard S. Methods for obtaining and using haplotype data
WO2003069431A2 (en) * 2002-02-14 2003-08-21 Medavante, Inc. System and method for facilitating candidate and subject participation in clinical trial studies
US7432355B2 (en) * 2002-08-09 2008-10-07 The J. David Gladstone Institutes Apolipoprotein E stable folding intermediate and methods of use thereof
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
AU2004248302B2 (en) * 2003-06-19 2009-07-30 Merck Serono Sa Use of prion conversion modulating agents
US20050038692A1 (en) * 2003-08-14 2005-02-17 Kane John Michael System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies
WO2005073892A2 (en) * 2004-01-16 2005-08-11 Disease Management Services, Plc Disease management system
US8466144B2 (en) 2004-07-16 2013-06-18 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
EP1915144A4 (en) * 2005-06-20 2009-08-19 Accera Inc METHOD FOR REDUCING OXIDATIVE DAMAGE AND IMPROVING MITOCHONDRIA EFFICIENCY
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
US20080126118A1 (en) * 2006-11-24 2008-05-29 General Electric Company, A New York Corporation Systems, methods and apparatus for a network application framework system
TWI362012B (en) * 2007-07-23 2012-04-11 System of providing hygienic education information and method thereof
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20090198504A1 (en) * 2008-02-05 2009-08-06 Medavante, Inc. Rater resource allocation systems and methods
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US9125881B2 (en) * 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010081825A2 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as an agent in cancer treatment
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
US20120078521A1 (en) * 2010-09-27 2012-03-29 General Electric Company Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
RU2467680C1 (ru) * 2011-10-04 2012-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования эффективности лечения больных ишемическим инсультом
US10665328B2 (en) 2014-06-30 2020-05-26 QIAGEN Redwood City, Inc. Methods and systems for interpretation and reporting of sequence-based genetic tests
US10658073B2 (en) 2014-08-15 2020-05-19 QIAGEN Redwood City, Inc. Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
WO2020091375A2 (ko) * 2018-10-29 2020-05-07 고려대학교 산학협력단 항우울제 추천 방법 및 시스템

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2716894B1 (fr) * 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease

Also Published As

Publication number Publication date
EP0946753B1 (en) 2004-06-09
CA2275404C (en) 2011-02-08
EP0948647A1 (en) 1999-10-13
AU745073B2 (en) 2002-03-14
EP0946753A2 (en) 1999-10-06
WO1998027226A2 (en) 1998-06-25
DE69729654D1 (de) 2004-07-29
AU5571798A (en) 1998-07-15
ATE269978T1 (de) 2004-07-15
DE69729473D1 (de) 2004-07-15
US6022683A (en) 2000-02-08
CA2275404A1 (en) 1998-06-25
CA2275504C (en) 2009-09-22
CA2275504A1 (en) 1998-06-25
EP0948647B1 (en) 2004-06-23
JP2009213482A (ja) 2009-09-24
WO1998027226A3 (en) 1998-08-20
JP5202429B2 (ja) 2013-06-05
AU5675798A (en) 1998-07-15
JP2012152229A (ja) 2012-08-16
WO1998027227A2 (en) 1998-06-25
US7001736B1 (en) 2006-02-21
JP2001524809A (ja) 2001-12-04
WO1998027227A3 (en) 1998-08-27
JP2013059347A (ja) 2013-04-04
DE69729654T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
DE69729473T2 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
DE69531557T2 (de) Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit
Dobson-Stone et al. CYLD is a causative gene for frontotemporal dementia–amyotrophic lateral sclerosis
Guidi et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease
Mosconi et al. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease
Craft et al. Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Papassotiropoulos et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia
Martins et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease
Corbo et al. Association of estrogen receptor α (ESR1) Pvu II and Xba I polymorphisms with sporadic Alzheimer’s disease and their effect on apolipoprotein E concentrations
Ferencz et al. The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age
Gatto et al. Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease
Singleton et al. Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies
Lanni et al. Influence of COMT Val158Met polymorphism on Alzheimer's disease and mild cognitive impairment in Italian patients
Li et al. CYP46A1 and the APOEε4 allele polymorphisms correlate with the risk of Alzheimer’s disease
US7049078B2 (en) Apolipoprotein E polymorphism and treatment of alzheimer's disease
Leduc et al. Involvement of paraoxonase 1 genetic variants in Alzheimer’s disease neuropathology
Nakayama et al. Apolipoprotein E phenotypes in healthy normal controls and demented subjects with Alzheimer’s disease and vascular dementia in Mie Prefecture of Japan
Juhasz et al. CYP46 T/C polymorphism is not associated with Alzheimer’s dementia in a population from Hungary
Wei et al. Associations of TFEB gene polymorphisms with cognitive function in rural Chinese population
EP1194589B1 (de) Dna-polymorphismen in sterol-regulator element-bindenden proteinen
AU733237B2 (en) Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease
Andrews Predicting Cognitive Decline: Genetic, Environmental and Lifestyle Risk Factors
Paisán-Ruiz Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35)
Price Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease
Johnston Relationships between the APOE (4) allele, cardiovascular disease, and Alzheimer's disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition